Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Mallinckrodt plc specializes in specialty pharmaceuticals, particularly in the areas of pain management and autoimmune disorders. The company has faced significant challenges, including a substantial decline in revenue and net income, largely due to competitive pressures and regulatory scrutiny surrounding its product portfolio, particularly its opioid medications.
Mallinckrodt generates revenue primarily through the sale of specialty and generic pharmaceuticals, with a focus on high-margin products. The company has historically leveraged its established relationships with healthcare providers and payers to maintain pricing power, although recent challenges have pressured margins.
Regulatory outcomes related to opioid litigation and settlements
Changes in reimbursement rates from Medicare and Medicaid
Market share shifts in specialty pharmaceuticals
New product approvals or pipeline developments
Increased regulatory scrutiny and potential changes in opioid-related legislation
Technological disruption in drug development processes
Intense competition from generic manufacturers
Emergence of new therapies that could replace existing products
High debt levels that could limit financial flexibility
Potential liquidity issues given the negative net margin
moderate - as a pharmaceutical company, Mallinckrodt's performance is somewhat insulated from economic cycles, but demand for its products can be affected by overall healthcare spending.
Higher interest rates can increase the company's financing costs, impacting its ability to invest in R&D and operational improvements, which could pressure valuations.
high - the company's significant debt levels (Debt/Equity of 1.30) make it sensitive to credit market conditions, affecting its refinancing options and overall financial stability.
value - investors may be attracted to the stock due to its low valuation metrics, despite the operational challenges.
high - the stock has exhibited extreme volatility, with a 1-year return of -97.8%, indicating significant investor uncertainty.
